Suppr超能文献

二甲双胍作为骨关节炎潜在的疾病修饰药物:临床前和人体研究的系统评价。

Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies.

机构信息

School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, 3004, Australia.

Alfred Hospital, Melbourne, VIC, 3004, Australia.

出版信息

Osteoarthritis Cartilage. 2022 Nov;30(11):1434-1442. doi: 10.1016/j.joca.2022.05.005. Epub 2022 May 18.

Abstract

OBJECTIVE

Osteoarthritis causes significant pain and disability with no approved disease-modifying drugs. We systematically reviewed the evidence from both pre-clinical and human studies for the potential disease-modifying effect of metformin in osteoarthritis.

METHODS

Ovid Medline, Embase and CINAHL were searched between inception and June 2021 using MeSH terms and key words to identify studies examining the association between metformin use and outcome measures related to osteoarthritis. Two reviewers performed the risk of bias assessment and 3 reviewers extracted data independently. Qualitative evidence synthesis was performed. This systematic review is registered on PROSPERO (CRD42021261052 and CRD42021261060).

RESULTS

Fifteen (10 pre-clinical and 5 human) studies were included. Most studies (10 pre-clinical and 3 human) assessed the effect of metformin using knee osteoarthritis models. In pre-clinical studies, metformin was assessed for the effect on structural outcomes (n = 10); immunomodulation (n = 5); pain (n = 4); and molecular pathways of its effect in osteoarthritis (n = 7). For human studies, metformin was evaluated for the effect on structural progression (n = 3); pain (n = 1); and immunomodulation (n = 1). Overall, pre-clinical studies consistently showed metformin having a chondroprotective, immunomodulatory and analgesic effect in osteoarthritis, predominantly mediated by adenosine monophosphate-activated protein kinase activation. Evidence from human studies, although limited, was consistent with findings in pre-clinical studies.

CONCLUSION

We found consistent evidence across pre-clinical and human studies to support a favourable effect of metformin on chondroprotection, immunomodulation and pain reduction in knee osteoarthritis. Further high-quality clinical trials are needed to confirm these findings as metformin could be a novel therapeutic drug for the treatment of osteoarthritis.

摘要

目的

骨关节炎会引起严重的疼痛和残疾,而目前尚无获批的可改变疾病进程的药物。我们系统地综述了临床前和人体研究中二甲双胍在骨关节炎中可能具有改变疾病进程作用的证据。

方法

我们使用 MeSH 术语和关键词在 Ovid Medline、Embase 和 CINAHL 中进行了检索,检索时间从建库开始至 2021 年 6 月,以确定研究二甲双胍使用与骨关节炎相关结局指标之间关联的研究。两名审查员进行了偏倚风险评估,3 名审查员独立提取数据。我们进行了定性证据综合。本系统评价已在 PROSPERO(CRD42021261052 和 CRD42021261060)上注册。

结果

共纳入 15 项(10 项临床前研究和 5 项人体研究)研究。大多数研究(10 项临床前研究和 3 项人体研究)采用膝关节骨关节炎模型评估二甲双胍的作用。在临床前研究中,评估了二甲双胍对结构结局的影响(n=10);免疫调节(n=5);疼痛(n=4);以及骨关节炎中其作用的分子途径(n=7)。对于人体研究,评估了二甲双胍对结构进展的影响(n=3);疼痛(n=1);和免疫调节(n=1)。总体而言,临床前研究一致表明,二甲双胍在骨关节炎中具有软骨保护、免疫调节和镇痛作用,主要通过腺苷单磷酸激活蛋白激酶的激活介导。尽管人体研究的证据有限,但与临床前研究的结果一致。

结论

我们在临床前和人体研究中均发现了一致的证据,支持二甲双胍对膝关节骨关节炎的软骨保护、免疫调节和疼痛缓解具有有利作用。需要进一步开展高质量的临床试验来证实这些发现,因为二甲双胍可能成为治疗骨关节炎的一种新的治疗药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验